Acorda and AstraZeneca claim victory over Mylan

The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Big Pharma

Mylan fails to void MSD diabetes treatment patent at PTAB

11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

Generics

AstraZeneca wins patent infringement case over Farxiga generic

19 October 2021 AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Big Pharma

Mylan fails to void MSD diabetes treatment patent at PTAB

11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

Generics

AstraZeneca wins patent infringement case over Farxiga generic

19 October 2021 AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Big Pharma

Mylan fails to void MSD diabetes treatment patent at PTAB

11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

Generics

AstraZeneca wins patent infringement case over Farxiga generic

19 October 2021 AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.